Journal article icon

Journal article

Single dose oral rofecoxib for acute postoperative pain in adults.

Abstract:

BACKGROUND: Editor's note: The anti-inflammatory drug rofecoxib (Vioxx) was withdrawn from the market at the end of September 2004 after it was shown that long-term use (greater than 18 months) could increase the risk of heart attack and stroke in a study of secondary prevention of adenoma recurrence. Further information is available at www.vioxx.com.Rofecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor previously licensed for treating acute and chronic pain; it was associated with fewe...

Expand abstract

Actions


Authors


More by this author
Institution:
University of Oxford
Department:
Oxford, MSD, Clinical Neuroscience
Role:
Author
Journal:
Cochrane database of systematic reviews (Online)
Issue:
4
Publication date:
2009-01-01
EISSN:
1469-493X
URN:
uuid:fc87af5e-884f-467f-aa96-133d67097cb5
Source identifiers:
243579
Local pid:
pubs:243579
Language:
English

Terms of use


Metrics


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP